Handa Pharmaceuticals Inc Statistics
Handa Pharmaceuticals Inc (6620) Stock Statistics & Valuation Metrics
Total Valuation
Handa Pharmaceuticals Inc has a market cap or net worth of TWD 17.35B. The enterprise value is TWD 7.88B.
- Market Cap
- TWD 17.35B
- Enterprise Value
- TWD 7.88B
Share Statistics
Handa Pharmaceuticals Inc has 165,981,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 165,981,900
- Owned by Insiders
- ―
- Owned by Institutions
- 0.21%
Financial Efficiency
Handa Pharmaceuticals Inc’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 12.92%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.13
- Return on Invested Capital (ROIC)
- 12.92%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 115.28M
- Profits Per Employee
- 49.98M
- Employee Count
- 15
- Asset Turnover
- 0.29
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Handa Pharmaceuticals Inc is 67.57. Handa Pharmaceuticals Inc’s PEG ratio is -1.12.
- PE Ratio
- 67.57
- PS Ratio
- 21.84
- PB Ratio
- 3.87
- Price to FCF
- 32.08
- Price to Operating Cash Flow
- 29.40
- PEG Ratio
- -1.12
Income Statement
In the last 12 months, Handa Pharmaceuticals Inc had revenue of 1.73B and earned 749.77M in profits. Earnings per share was 4.85.
- Revenue
- 1.73B
- Gross Profit
- 1.46B
- Operating Income
- 934.18M
- Pretax Income
- 936.98M
- Net Income
- 749.77M
- EBITDA
- 1.10B
- Earnings Per Share (EPS)
- 4.85
Cash Flow
In the last 12 months, operating cash flow was 662.01M and capital expenditures -28.72M, giving a free cash flow of 633.29M billion.
- Operating Cash Flow
- 662.01M
- Free Cash Flow
- 633.29M
- Free Cash Flow per Share
- 4.07
Dividends & Yields
Handa Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of 1.98%
- Dividend Per Share
- ―
- Dividend Yield
- 1.98%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.40%
- Earnings Yield
- 2.63%
Stock Price Statistics
- Beta
- 1.04
- 52-Week Price Change
- -18.04%
- 50-Day Moving Average
- 127.14
- 200-Day Moving Average
- 89.98
- Relative Strength Index (RSI)
- 36.84
- Average Volume (3m)
- 2.87M
Important Dates
Handa Pharmaceuticals Inc upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- May 07, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Handa Pharmaceuticals Inc as a current ratio of 36.59, with Debt / Equity ratio of 0.84%
- Current Ratio
- 36.59
- Quick Ratio
- 36.59
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.59
- Interest Coverage Ratio
- 424.24
Taxes
In the past 12 months, Handa Pharmaceuticals Inc has paid 187.20M in taxes.
- Income Tax
- 187.20M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Handa Pharmaceuticals Inc EV to EBITDA ratio is 27.31, with an EV/FCF ratio of 27.09.
- EV to Sales
- 14.16
- EV to EBITDA
- 27.31
- EV to Free Cash Flow
- 27.09
- EV to Operating Cash Flow
- 25.91
Balance Sheet
Handa Pharmaceuticals Inc has TWD 3.73B in cash and marketable securities with TWD 41.03M in debt, giving a net cash position of TWD 3.69B billion.
- Cash & Marketable Securities
- TWD 3.73B
- Total Debt
- TWD 41.03M
- Net Cash
- TWD 3.69B
- Net Cash Per Share
- TWD 22.22
- Tangible Book Value Per Share
- TWD 26.59
Margins
Gross margin is 82.46%, with operating margin of 29.80%, and net profit margin of 31.99%.
- Gross Margin
- 82.46%
- Operating Margin
- 29.80%
- Pretax Margin
- 43.16%
- Net Profit Margin
- 31.99%
- EBITDA Margin
- 38.82%
- EBIT Margin
- 29.80%
